GWU INTERIM GUIDANCE
ANTICOAGULATION PROTOCOL for COVID-19 Non-Critically ill Patients

INCLUSION: All admitted COVID-19 patients and:
1. Platelets > 50,000
2. Hg > 8.0 g/dl
3. GFR > 30

EXCLUSION: 1. History of Child-Pugh Class C liver disease
2. History or evidence of current or recent bleeding
3. INR > 1.5

Does COVID-19 patient meet all criteria?

YES

Assess D-dimer

D-dimer < 3µg/ml

Usual Thromboprophylaxis

NO

If no contraindications, consider usual thromboprophylaxis

D-dimer > 3µg/ml

Obtain daily CBC, D-dimer

Rising D-dimer -and/or-
Clinical deterioration/ \( \uparrow \) O2 requirement

Consider Therapeutic Anticoagulation

- Enoxaparin 1.5 mg/kg/day

Consider (continuing) therapeutic dosing for 2 weeks post-discharge (option: apixaban 5 mg po bid) for patients on therapeutic anticoagulation while hospitalized (Rivaroxaban if not covered by insurance)